Section Arrow
Quote
REGN.NASDAQ
- Regeneron Pharmaceuticals
Quotes are at least 15-min delayed:2026/01/07 03:38 EST
Regular Hours
Last
 776.54
+13.31 (+1.74%)
Day High 
787.656 
Prev. Close
763.23 
1-M High
792.77 
Volume 
935.12K 
Bid
--
Ask
--
Day Low
763.195 
Open
764.35 
1-M Low
691.86 
Market Cap 
80.22B 
Currency 美元 
P/E 18.29 
%Yield 0.45 
10-SMA 776.7 
20-SMA 754.65 
50-SMA 714.82 
52-W High 792.77 
52-W Low 476.4869 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
41.72/46.12
Enterprise Value
82.92B
Balance Sheet
Book Value Per Share
294.56
Cash Flow
Cash Flow Yield
0.06
Income Statement
Total Revenue
14.20B
Operating Revenue Per Share
124.62
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
CYCNCyclerion Therapeutics1.95+0.57+41.30%-- 
ALMSAlumis Inc.16.23+7.92+95.31%0.33PE
MREOMereo BioPharma Group plc0.379-0.1016-21.14%-- 
SLSSELLAS Life Sciences Group4.1-0.9-18.00%-- 
RXRXRecursion Pharmaceuticals4.55+0.18+4.12%-- 
Industry overview quotes are at least 15 minutes delayed
Business Description
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approvedfor wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has early-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.